Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · IEX Real-Time Price · USD

8.79

+0.45 (5.40%)

At close: May 2, 2024, 4:00 PM

8.81

+0.02 (0.23%)

After-hours: May 2, 2024, 7:55 PM EDT

Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	394.8	551.19	286.67	264.13	75.17
Short-Term Investments	0	0	231.45	0	0
Cash & Cash Equivalents	394.8	551.19	518.11	264.13	75.17
Cash Growth	-28.37%	6.38%	96.16%	251.37%	-
Receivables	3.09	2.75	9.09	0.16	0.15
Other Current Assets	40.25	15.87	7.51	2.16	1.08
Total Current Assets	438.14	569.81	534.72	266.44	76.4
Property, Plant & Equipment	120.17	121.45	64.73	25.97	24.37
Long-Term Investments	6.63	7.92	8.68	3.04	0
Goodwill and Intangibles	88.5	2.11	2.19	2.49	0
Other Long-Term Assets	0.26	0	0.04	0.65	0.66
Total Long-Term Assets	215.56	131.47	75.63	32.15	25.03
Total Assets	653.7	701.29	610.35	298.59	101.43
Accounts Payable	3.95	4.59	2.82	1.07	1.26
Deferred Revenue	87.66	126.99	16.67	16.67	0
Current Debt	6.16	6.05	0.09	11.07	0.08
Other Current Liabilities	-4.6	-37.36	27.08	-5.72	5.35
Total Current Liabilities	93.17	100.27	46.66	23.1	6.68
Long-Term Debt	44.52	44.96	9.97	11.41	12.42
Other Long-Term Liabilities	52.58	70.26	10.78	22.05	5.49
Total Long-Term Liabilities	97.09	115.22	20.75	33.46	17.9
Total Liabilities	190.26	215.48	67.41	56.56	24.59
Total Debt	50.67	51.01	10.06	22.49	12.5
Debt Growth	-0.65%	406.91%	-55.25%	79.97%	-
Retained Earnings	-967.62	-639.56	-400.08	-213.6	-126.6
Comprehensive Income	0	0	-0.13	0	0
Shareholders' Equity	463.44	485.81	542.94	-206.29	-124.27
Net Cash / Debt	344.12	500.19	508.05	241.64	62.68
Net Cash / Debt Growth	-31.20%	-1.55%	110.25%	285.54%	-
Net Cash Per Share	1.66	2.85	4.05	11.09	2.91
Working Capital	344.97	469.55	488.06	243.34	69.71
Book Value Per Share	2.23	2.77	4.33	-9.47	-5.76

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).